Alacris Theranostics GmbH is a systems medicine company specialised in developing innovative approaches for cancer precision medicine, biomarker discovery and drug development. With its award-winning portfolio of technologies, Alacris delivers a unique combination of deep molecular insight and predictive modelling that is set to shape the cancer care landscape, from diagnosis and treatment to drug development. The company’s flagship products include its Comprehensive Molecular Tumour Analysis (CMTA) service, which offers an unparalleled depth of molecular analysis and provides clinicians with the necessary information to support their treatment decisions. Alacris moves beyond the state-of-the-art, deploying the computational modelling tool, ModCellTM, to simulate patient-specific drug responses. ModCellTM offers deep insight into cellular signalling during health and disease, facilitating discovery of new clinical applications for targeted patient treatment and efficient drug development. Alacris Theranostics aims to shift the current cancer management paradigm and translate innovation into direct benefits for patients, by providing solutions that address the needs of clinicians, academics and the pharmaceutical industry, worldwide. See www.alacris-theranostics.com for further information.